DUBLIN, October 20, 2021--(BUSINESS WIRE)--The "Global Intravenous Iron Drugs Market Size, Share & Trends Analysis Report by Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), by Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
The global intravenous iron drugs market size is expected to reach USD 4.2 billion by 2028 and is expected to expand at a CAGR of 8.5% from 2021 to 2028.
The introduction of novel formulations with expanded indications, increasing R&D activities, and rising awareness for diagnosis and treatment of anemia is expected to propel market demand over the forecast period.
The increase in the prevalence of chronic diseases, such as chronic kidney disease, cancer, inflammatory bowel diseases, diabetes, and acute and chronic infections, has been a major market driver facilitating a significant demand for intravenous iron drugs.
According to the Globol can estimates, in 2020, around 19,292,789 new cases of cancer were diagnosed globally, which lead to around 9,958,133 deaths in the same year. According to the data published by the CDC, in 2019, an estimated 15% of U.S. adults, or around 37 million adults, are suffering from chronic kidney disease (CKD).
The same source also stated that diabetes and high blood pressure are the major causes of CKD in adults, and CKD is more common in people aged 65 years or older. The rise in the incidence of chronic kidney disease globally, due to unhealthy lifestyles, has been a major growth factor for the market.
Furthermore, increasing approval and indication expansion of iron drugs in key markets has significantly supported market growth. In February 2021, Pharmacosmos announced that the National Medical Products Administration (NMPA) approved Monofer injection 100 mg/mL in China.
Also, in February 2018, the company announced that the U.S. FDA approved Supplemental New Drug Application (sNDA) for Feraheme (ferumoxytol injection). The FDA approved the use of Feraheme by an eligible adult suffering from Iron Deficiency Anemia (IDA).
Intravenous Iron Drugs Market Report Highlights
Effects of the ongoing pandemic have also shown an estimated 14.0% to 30.0% kidney function loss among COVID-19 patients. Thus, increased the demand for iron drugs for the management of kidney disease-induced anemia in COVID-19 patients
The Ferric Carboxymaltose segment accounted for the largest revenue share in 2020. Its high share is attributed to the high revenue generation of Ferinject/Injectafer in key markets
The Chronic Kidney Disease (CKD) segment dominated the market in 2020. Its leading share is attributed to the increasing prevalence of CKD and the high incidence of IDA among CKD patients
Key players are undertaking extensive strategic initiatives in the market, such as mergers and acquisitions, new product developments, and regional expansion, to address the growing demand
North America dominated the market with the largest revenue share in 2020. The presence of major players and favorable reimbursement scenarios are facilitating the dominance of this region during the study period
Asia Pacific is projected to witness a lucrative CAGR owing to the high prevalence of IDA in emerging economies
Market driver analysis
Increasing prevalence of target diseases
Increasing prevalence of iron deficiency anemia
Disadvantages of oral iron drugs
Market Restraint Analysis
Side effects associated with iron drugs
Daiichi Sankyo Company, Ltd.
Vifor Pharma Management Ltd.
Shield Therapeutics Plc.
For more information about this report visit https://www.researchandmarkets.com/r/97rdyk
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005822/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900